111 related articles for article (PubMed ID: 12162720)
1. Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
Zhou S; Kestell P; Paxton JW
J Pharm Pharmacol; 2002 Jul; 54(7):997-1003. PubMed ID: 12162720
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
[TBL] [Abstract][Full Text] [Related]
4. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Paxton JW; Tingle MD; Kestell P
Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
[TBL] [Abstract][Full Text] [Related]
5. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
[TBL] [Abstract][Full Text] [Related]
6. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.
Miners JO; Valente L; Lillywhite KJ; Mackenzie PI; Burchell B; Baguley BC; Kestell P
Cancer Res; 1997 Jan; 57(2):284-9. PubMed ID: 9000569
[TBL] [Abstract][Full Text] [Related]
7. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
Zhou S; Kestell P; Paxton JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Sep; 776(2):231-6. PubMed ID: 12138005
[TBL] [Abstract][Full Text] [Related]
8. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
Zhou S; Paxton JW; Kestell P; Tingle MD
J Pharm Pharmacol; 2001 Apr; 53(4):463-71. PubMed ID: 11341362
[TBL] [Abstract][Full Text] [Related]
9. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
Zhou SF; Tingle MD; Kestell P; Paxton JW
Xenobiotica; 2002 Feb; 32(2):87-107. PubMed ID: 11868972
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
11. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Woon ST; Baguley BC; Palmer BD; Fraser JD; Ching LM
Oncol Res; 2002; 13(2):95-101. PubMed ID: 12392157
[TBL] [Abstract][Full Text] [Related]
12. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Kestell P; Baguley BC; Paxton JW
Biochem Pharmacol; 2003 Jun; 65(11):1853-65. PubMed ID: 12781337
[TBL] [Abstract][Full Text] [Related]
13. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.
Zhou S; Feng X; Kestell P; Paxton JW; Baguley BC; Chan E
Eur J Pharm Sci; 2005 Apr; 24(5):513-24. PubMed ID: 15784341
[TBL] [Abstract][Full Text] [Related]
14. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
Zhou S; Chin R; Kestell P; Tingle MD; Paxton JW
Br J Clin Pharmacol; 2001 Aug; 52(2):129-36. PubMed ID: 11488768
[TBL] [Abstract][Full Text] [Related]
15. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
Zhou SF; Paxton JW; Tingle MD; Kestell P; Jameson MB; Thompson PI; Baguley BC
Xenobiotica; 2001 May; 31(5):277-93. PubMed ID: 11491389
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
17. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Zhou S; Kestell P; Tingle MD; Ching LM; Paxton JW
Cancer Chemother Pharmacol; 2001 Jun; 47(6):541-4. PubMed ID: 11459209
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zho S; Chiang D; Chin R; Kestell P; Paxton JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Feb; 767(1):19-26. PubMed ID: 11863291
[TBL] [Abstract][Full Text] [Related]
19. Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
Zhou S; Feng X; Kestell P; Baguley BC; Paxton JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):87-97. PubMed ID: 15282097
[TBL] [Abstract][Full Text] [Related]
20. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Zhou S; Kestell P; Paxton JW
Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
